Résultats de recherche
Il y a 1 jour · Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug MT May. 30: Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union CI
Il y a 5 jours · Pharming Group N.V. Provides Revenue Guidance for 2024 May. 08: CI Pharming Group N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 May. 08: CI Pharming Group to Buy Back EUR123 Million of Bonds due 2025
Il y a 5 jours · 31/05 Pharming Group signale un retard dans l'examen par l'UE d'un médicament rare contre l'immunodéficience MT 30/05 Pharming Group N.V. fait le point sur l'examen réglementaire en cours du ...
Il y a 1 jour · Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug MT May. 30: Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union CI
Il y a 5 jours · De koers van Pharming Group (Aandeel, AEX) met nieuwsberichten, columns, agenda, forum, technische analyse, fundamentele analyse, opties, turbo's, speeders, sprinters ...
Il y a 23 heures · Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug MT May. 30: Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union CI
Il y a 5 jours · Review Pharming Group (PHARM:XAMS) stock's current information regarding return on assets, equity, invested capital, margins, and turnover over the last fiscal year.
